Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy
- 2nd Edition - April 17, 2018
- Latest edition
- Editor: Herbert B. Newton
- Language: English
Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Second Edition, provides a comprehensive overview of the molecular methodologies in the neuro-onc… Read more
Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Second Edition, provides a comprehensive overview of the molecular methodologies in the neuro-oncology field. There have been profound changes in the landscape of approaches to brain tumor therapy since the first edition—mainly in the areas of molecular biology and molecular therapeutics, as well as in the maturation of immunotherapy approaches (e.g., vaccines). This updated edition has a new, primary focus on multidisciplinary molecular methods, and is broadened to include the latest cutting-edge molecular biology, therapeutics, immunobiology and immunotherapy approaches.
As the first comprehensive book to address the molecular research into these concepts, users will find it to be an invaluable resource on the topics discussed.
- Provides the most up-to-date information regarding conventional forms of cytotoxic chemotherapy, as well as the basic science and clinical application of molecular therapeutics for the treatment of brain tumors
- Broadly appeals to anyone interested in neuro-oncology and the treatment of brain tumors
- Features updated chapters on molecular biology, molecular therapeutics, maturation of immunotherapy approaches, and a focus on multidisciplinary molecular methods
- Includes a new section on the basic science of immunology, as well as thorough updates on the use of vaccine technology and immunotherapy for the treatment of brain tumors
Neuroscientists, neurobiologists, neuro-oncologists, neurologists, post-doctoral fellows, researchers, graduate students in biological and biomedical sciences
SECTION I. PHARMACOLOGICAL AND CLINICAL APPLICATIONS1. Overview of Brain Tumor Epidemiology and Histopathology2. Clinical Pharmacology of Brain Tumor Chemotherapy3. Antiepileptic drugs and chemotherapy: Potential interactions and impact on treatment of patients with cancer4. Brain Tumor Models for Cancer Therapy5. Genomics and proteomics in neuro-oncology6. Chemotherapy Resistance7. Clinical Trial Design and Implementation in Neuro-Oncology8. Biology of the Blood-Brain and Blood-Brain Tumor Barriers
SECTION II. INNOVATIVE CHEMOTHERAPY DELIVERY9. Intra-arterial Chemotherapy10. Blood-Brain Barrier Disruption Chemotherapy11. Interstitial Chemotherapy and Polymer-Drug Delivery12. Intratumoral Chemotherapy and Convection-Enhanced Delivery13. Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue in Brain Tumors14. CSF Dissemination of Primary Brain Tumors 15. Gene/Viral Treatment Approaches for Malignant Brain Cancer16. Nanoparticles as Therapeutic Agents for Brain Tumors
SECTION III. MOLECULAR BIOLOGY AND MOLECULAR THERAPEUTICS17. Overview of Molecular Genetics of Brain Tumors18. Cell Cycle Regulation19. Targeting cell cycle proteins in brain cancer20. Apoptosis Pathways and Chemotherapy in Brain Tumors21. Growth Factor Signaling Pathways and Targeted Therapy22. Targeting the RAS-RAF-MEK-ERK Signaling Pathway in Gliomas23. PI3-kinase, Akt, mTOR and Treatment24. Scatter Factor/HGF and C-MET in Glioblastoma25. Targeting the sonic hedgehog pathway in brain cancers: Advances, limitations, and future directions26. Angiogenesis and angiogenesis inhibitors in brain tumors27. Bevacizumab and Brain Tumors28. Histone Deacetylase Inhibitors as Therapeutic Agents
SECTION IV. CHEMOTHERAPY FOR SPECIFIC TUMORS – ADULTS 29. Historial and conventional chemotherapy approaches for high grade astrocytomas 30. The use of temozolomide for chemo-radiation and adjuvant therapy of high-grade gliomas31. Molecular Treatment of High-Grade Glioma32. Chemotherapy of Low-Grade Astrocytomas33. Chemotherapy of Oligodendrogliomas34. Chemotherapy of Primary Central Nervous System Lymphoma35. Chemotherapy for Medulloblastoma in Adults36. Chemotherapy of Adult Ependymoma 37. Chemotherapy for Glioneuronal Tumors38. Medical therapy of Schwannomas 39. Chemotherapy of Pineal Parenchymal Tumors40. Chemotherapy of Meningiomas41. Chemotherapy of Brain Metastases
SECTION V. CHEMOTHERAPY FOR SPECIFIC TUMORS – PEDIATRICS42. Chemotherapy of Pediatric Low-Grade Gliomas43. Chemotherapy of Pediatric High-Grade Gliomas44. Chemotherapy for Medulloblastoma45. Chemotherapy of Brainstem Gliomas46. Germ Cell Tumors47. Chemotherapy of Ependymoma – Childhood48. Chemotherapy for CNS Atypical Teratoid/Rhabdoid Tumor49. Chemotherapy of Central Nervous System Primitive Neuro-Ectodermal Tumors50. Pediatric Choroid Plexus Carcinoma: Current Management and Future Directions
SECTION VI. IMMUNOTHERAPY OF BRAIN TUMORS51. The Immune Response to Glioblastoma: Overview and Focus on Checkpoint Blockade52. Blockade of the Checkpoint Inhibitor Pathways and Activated T-cell Therapy in Brain Tumors53. Overview of Dendritic Cell Vaccines for Brain Tumors54. Overview of Vaccine Strategies against Epidermal Growth Factor Receptor in Brain Tumors55. Overview of CNS Vaccines – Pediatrics
SECTION VII. RESPONSE ASSESSMENT, QUALITY OF LIFE, AND NEUROPSYCHOLOGY56. Issues in Response Assessment of Brain Tumor Chemotherapy57. Pseudoprogression in Neuro-Oncology: Overview, Pathophysiology, and Interpretation58. Response assessment in neuro-oncology (RANO): An update 59. Immunotherapy Response Assessment in Neuro-Oncology (iRANO)60. Quality of Life in Neuro-Oncology61. Neuropsychology of Chemotherapy in Brain Tumor Patients
- Edition: 2
- Latest edition
- Published: April 17, 2018
- Language: English
HN
Herbert B. Newton
Herbert B. Newton, M.D., FAAN, is currently the Medical Director for the Neuro-Oncology Program and Brain Tumor Institute at the University Hospitals Cleveland Medical Center and Seidman Cancer Center, in Cleveland, Ohio, where he is also a Professor of Neurology and Solid Tumor Oncology, and holds the William Burton Risman Neurological Institute Chair in Memory and Cognition. Prior to that he was the Director of the Neuro-Oncology Center and Medical Neuro-Oncology Program at the Advent Health Cancer Institute and Advent Health Orlando Campus in Orlando, Florida. He is also retired as a Professor of Neurology and Neurosurgery, Dardinger Neuro-Oncology Center, Esther Dardinger Endowed Chair in Neuro-Oncology and Division of Neuro-Oncology at the Ohio State University Medical Center and James Cancer Hospital, in Columbus, Ohio. He is a Diplomate of the American Board of Psychiatry and Neurology, a Fellow of the American Academy of Neurology and Royal Society of Medicine, and a member of numerous national and international societies.
Affiliations and expertise
Neuro-Oncology Program and Brain Tumor Institute at the University Hospitals Cleveland Medical Center and Seidman Cancer CenterRead Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy on ScienceDirect